US 6093570A
· Ferrari et al.
· 2000
[cited by applicant]
US 6458587B2
· Ferrari et al.
· 2002
[cited by applicant]
US 6951758B2
· Ferrari et al.
· 2005
[cited by applicant]
US 7439065B2
· Ferrari et al.
· 2008
[cited by applicant]
US 7541188B2
· Conrad
· 2009
[cited by examiner]
US 8834423B2
· Falo, Jr. et al.
· 2014
[cited by applicant]
US 20050053971A1
· Chenchik
· 2005
[cited by examiner]
US 20140350472A1
· Falo, Jr. et al.
· 2014
[cited by applicant]
WO WO2015189205A1
· 2015
[cited by examiner]
Uhrich, K. E., and D. Abdelhamid. “Biodegradable and bioerodible polymers for medical applications.” Biosynthetic polymers for medical applications. Woodhead Publishing, 2016. 63-83. (Year: 2016).
[cited by examiner]
Ward et al. The human cytomegalovirus immediate-early promoter is transcriptionally active in undifferentiated mouse embryonic stem cells. Stem Cells, vol. 20, No. 5, pp. 472-475, Sep. 2002. (Year: 2002).
[cited by examiner]
Han et al. A combined therapeutic approach for pyruvate dehydrogenase deficiency using self-complementary adeno-associated virus serotype-specific vectors and dichloroacetate. Molecular Genetics and Metabolism, vol. 93,…
[cited by examiner]
Shcherbakova et al. Near-infrared fluorescent proteins for multicolor in vivo imaging. Nature Methods, vol. 10, No. 8, pp. 751-754, pp. 1/3-3/3 of Online Methods, and pp. 1-14 of Supplementary Information, Jun. 16, 2013…
[cited by examiner]
DeMuth et al. Polymer multilayer tattooing for enhanced DNA vaccination. Nature Materials, vol. 12, pp. 367-376, Jan. 27, 2013. (Year: 2013).
[cited by examiner]
Meyer-Ficca, M. L., Meyer, R. G., Kaiser, H., Brack, A. R., Kandolf, R., & Küpper, J.-H. (2004). Comparative analysis of inducible expression systems in transient transfection studies. Analytical Biochemistry, 334(1), 9…
[cited by examiner]
Alberts et al., “Rapid transcriptional assay for the expression of two distinct reporter genes by microinjection”, DNA and Cell Biology, 1993, pp. 935-943, vol. 12:10.
[cited by applicant]
Allez et al., “Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects”, Journal of Crohn's and Colitis, 2010, pp. 355-366…
[cited by applicant]
Altwegg et al., “TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease”, Mediators of Inflammation, 2014, pp. 1-8, vol. 2014, Article ID 172821.
[cited by applicant]
Al-Zahrani et al., “Microneedle-mediated vaccine delivery: Harnessing cutaneous immunobiology to improve efficacy”, Expert Opin Drug Deliv., 2012, pp. 541-550, vol. 9:5.
[cited by applicant]
Angst et al., “Cytokine profile in human skin in response to experimental inflammation, noxious stimulation, and administration of a COX-inhibitor: A microdialysis study”, Pain, 2008, pp. 15-27, vol. 139.
[cited by applicant]
Aud et al., “Mechanisms of Disease: transcription factors in inflammatory arthritis”, Nature Clinical Practice Rheumatology, 2006, pp. 434-442, vol. 2:8.
[cited by applicant]
Averbeck et al., “In situ profiling and quantification of cytokines released during ultraviolet B-induced inflammation by combining dermal microdialysis and protein microarrays”, Experimental Dermatology, 2006, pp. 447-…
[cited by applicant]
Ayuso, “Manufacturing of recombinant adeno-associated viral vectors: new technologies are welcome”, Molecular Therapy—Methods & Clinical Development, 2016, pp. 1-3, vol. 3:15049.
[cited by applicant]
Barton et al., “TL Ymphocyte Effector Mechanisms in the Retina in Posterior Uveitis”, Eye, 1994, pp. 60-65, vol. 8.
[cited by applicant]
Bediz et al., “Dissolvable Microneedle Arrays for Intradermal Delivery of Biologics: Fabrication and Application”, Dharm Res, 2014, pp. 117-135, vol. 31:1.
[cited by applicant]
Bendtzen et al., “Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies”, Scandinavian Journal of Gastroentero…
[cited by applicant]
Bendtzen, “Personalized Medicine: Theranostics {Therapeutics Diagnostics) Essential for Rational Use of Tumor Necrosis Factor-alpha Antagonists”, Discovery Medicine, 2013, pp. 201-211, vol. 15:83.
[cited by applicant]
Bengtson et al., “A Differential Fluorescent Receptor for Nucleic Acid Analysis”, Chembiochem, 2014, pp. 228-231, vol. 15:2.
[cited by applicant]
Bhinge et al., “Mapping the chromosomal targets of STAT1 by Sequence Tag Analysis of Genomic Enrichment (STAGE)”, Genome Research, 2007, pp. 910-916, vol. 17.
[cited by applicant]
Bodenlenz et al., “Dermal PK/PD of a lipophilic topical drug in psoriatic patients by continuous intradermal membrane-free sampling”, European Journal of Pharmaceutics and Biopharmaceutics, 2012, pp. 635-641, vol. 81.
[cited by applicant]
Boukamp et al., “Normal Keratinization in a Spontaneously Immortalized Aneuploid Human Keratinocyte Cell Line”, The Journal of Cell Biology, 1988, pp. 761-771, vol. 106.
[cited by applicant]
Bryne et al., “JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update”, Nucleic Acids Research, 2008, pp. D102-D106, vol. 36 (Database issue).
[cited by applicant]
Campbell et al., “Tissue engineering with the aid of inkjet printers”, Expert Opinion on Biological Therapy, 2007, pp. 1123-1127, vol. 7:8.
[cited by applicant]
Camporeale et al., “IL-6, IL-17 and STAT3: a holy trinity in auto-immunity?”, Frontiers in Bioscience (Landmark Ed), 2012, pp. 2306-2326, vol. 17.
[cited by applicant]
Caprioli et al., “Cytokine Therapies in Crohn's Disease: Where are We Now and where should We Go?”, Inflammation & Allergy—Drug Targets, 2011, pp. 47-53, vol. 10.
[cited by applicant]
Caprioli et al., “Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases”, British Journal of Pharmacology, 2012, pp. 820-828, vol. 165.
[cited by applicant]
Chan et al., “Comparison of IRES and F2A-Based Locus-Specific Multicistronic Expression in Stable Mouse Lines”, PLoS One, 2011, pp. 1-11, vol. 6:12.
[cited by applicant]
Chen et al., “A General System for Automatic Biomedical Image Segmentation Using Intensity Neighborhoods”, International Journal of Biomedical Imaging, 2011, pp. 1-13, vol. 2011.
[cited by applicant]
Cheng et al., “Principles Of Regulatory Information Conservation Between Mouse And Human”, Nature, 2014, pp. 371-375, vol. 515:7527.
[cited by applicant]
Chosdol et al., “Nuclear Factors Linking Cancer and Inflammation”, Nuclear Signaling Pathways and Targeting Transcription in Cancer. Cancer Drug Discovery and Development. Humana Press. New York, NY, 2014, pp. 121-154.
[cited by applicant]
Chtarto et al., “An Adeno-Associated Virus-Based Intracellular Sensor of Pathological Nuclear Factor-KB Activation for Disease-Inducible Gene Transfer”, PLOS ONE, 2013, pp. 1-15, vol. 8:1.
[cited by applicant]
Chtarto et al., “Tetracycline-inducible transgene expression mediated by a single AAV vector”, Gene Therapy, 2003, pp. 84-94, vol. 10.
[cited by applicant]
Cooper et al., “Inkjet-Based Biopatterning of Bone Morphogenetic Protein-2 to Spatially Control Calvarial Bone formation”, Tissue Engineering: Part A, 2010, pp. 1749-1759, vol. 6:5.
[cited by applicant]
Coulman et al., “Minimally invasive cutaneous delivery of macromolecules and plasmid DNA via microneedles”, Current Drug Delivery, 2006, pp. 65-75, vol. 3.
[cited by applicant]
Deyrieux et al., “In vitro culture conditions to study keratinocyte differentiation using the HaCaT cell line”, Cytotechnology, 2007, pp. 77-83, vol. 54.
[cited by applicant]
Ding et al., “Anti-Interleukin-6 Receptor Antibody Treatment in Inflammatory Autoimmune Diseases”, Reviews on Recent Clinical Trials, 2006, pp. 193-200, vol. 1.
[cited by applicant]
Ding et al., “Proteome-wide profiling of activated transcription factors with a concatenated tandem array of transcription factor response elements”, PNAS, 2013, pp. 6771-6776, vol. 110:17.
[cited by applicant]
Ellis et al. “A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype”, Virolog…
[cited by applicant]
Euskirchen et al., “Mapping of transcription factor binding regions in mammalian cells by ChIP: comparison of array- and sequencing-based technologies”, Genome Research, 2007, pp. 898-909, vol. 17.
[cited by applicant]
Ferguson et al., “Housekeeping proteins: A preliminary study illustrating some limitations as useful references in protein expression studies”, Proteomics, 2005, pp. 566-571, vol. 5.
[cited by applicant]
Filonov et al., “Bright and stable near-infrared fluorescent protein for in vivo imaging”, Nat Biotechnol, 2012, pp. 757-761, vol. 29:8.
[cited by applicant]
Gallagher et al., “Biological response modifier therapy for refractory childhood uveitis”, Br J Ophthalmol, 2007, pp. 1341-1344, vol. 91.
[cited by applicant]
Gene Synthesis Handbook, Second Edition, GenScript USA, Inc., 2014.
[cited by applicant]
Genovese et al., “Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study”, Ann Rheum Dis, 2014, pp. 1607-16…
[cited by applicant]
Gilmore et al., “NF-κB: where did it come from and why?”, Immunological Reviews, 2012, pp. 14-35, vol. 246.
[cited by applicant]
Gray et al., “Production of Recombinant Adeno-Associated Viral Vectors and Use in In Vitro and In Vivo Administration”, Curr Protoc Neurosci., 2011, pp. 1-36, Chapter: Unit 4.17.
[cited by applicant]
Grigorov et al., “Rapid Titration of Measles and Other Viruses: Optimization with Determination of Replication Cycle Length”, PLoS One, 2011, pp. 1-12, vol. 6:9.
[cited by applicant]
Guo et al., “Rapid and simplified purification of recombinant adeno-associated virus”, J Virol Methods, 2012, pp. 139-146, vol. 183:2.
[cited by applicant]
Hadam et al., “Managing risks of TNF inhibitors: An update for the internist”, Cleveland Clinic Journal of Medicine, 2014, pp. 115-127, vol. 81:2.
[cited by applicant]
Halter et al., “Automated Live Cell Imaging of Green Fluorescent Protein Degradation in Individual Fibroblasts”, Cytometry Part A, 2007, pp. 827-834, vol. 71A.
[cited by applicant]
Hareendran et al., “Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them”, Reviews in Medical Virology, 2013, pp. 399-413, vol. 23.
[cited by applicant]
Heinz et al., “Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities”, Mol Cell, 2010, pp. 576-589, vol. 38:4.
[cited by applicant]
Herberg et al., “Inkjet-based biopatterning of SDF-1beta augments BMP-2-induced repair of critical size calvarial pone defects in mice”, Bone, 2014, pp. 95-103, vol. 67.
[cited by applicant]
Hofmann et al., “Efficient gene transfer into human hepatocytes by baculovirus vectors”, Proc. Natl. Acad. Sci. USA, 1995, pp. 10099-10103, vol. 92.
[cited by applicant]
Jia et al., “Electrochemical Tattoo Biosensors for Real-Time Noninvasive Lactate Monitoring in Human Perspiration”, Analytical Chemistry, 2013, pp. 6553-6560, vol. 85.
[cited by applicant]
Tincani et al., “Inflammatory molecules: a target for treatment of systemic autoimmune diseases”, Autoimmunity Reviews, 2007, pp. 1-7, vol. 7.
[cited by applicant]
Voorhees et al., “A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma”, Br J Haematol, 2013, pp. 357-366, vol. 161:3.
[cited by applicant]
Wang et al., “Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors”, Genome Research, 2012, pp. 1798-1812, vol. 22.
[cited by applicant]
Wen et al., “The Role of the Transcription Factor CREB in Immune Function”, J Immunol, 2010, pp. 6413-6419, vol. 185.
[cited by applicant]
Wieder et al., “Optimization of Reporter Cells for Expression Profiling in a Microfluidic Device”, Biomedical Microdevices, 2005, pp. 213-222, vol. 7:3.
[cited by applicant]
Xia et al., “In vitro- and In Vivo-Induced Transgene Expression in Human Embryonic Stem Cells and Derivatives”, Stem Cells, 2008, pp. 525-533, vol. 26:2.
[cited by applicant]
Xiao et al., “Quantitative 3D Tracing of Gene-delivery Viral Vectors in Human Cells and Animal Tissues”, Molecular Therapy, 2012, pp. 317-328, vol. 20:2.
[cited by applicant]
Xu et al., “Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells”, Cancer Letters, 2014, pp. 172-178, vol. 343.
[cited by applicant]
Yokota et al., “Pathogenesis of Systemic Inflammatory Diseases in Childhood: Lessons From Clinical Trials of Anti-Cytokine Monoclonal Antibodies for Kawasaki Disease, Systemic Onset Juvenile Idiopathic Arthritis, and Cr…
[cited by applicant]
Zhou et al., “Cytokine biosensors: the future of infectious disease diagnosis?”, Expert Rev. Anti Infect Ther, 2012, pp. 1079-1081, vol. 10:0.
[cited by applicant]
Zhu et al., “Electrochemical Sensors and Biosensors Based on Nanomaterials and Nanostructures”, Analytical Chemistry, 2014, pp. 230-249, vol. 87.
[cited by applicant]
Jiang et al., “Tight regulation from a single tet-off rAAV vector as demonstrated by flow cytometry and quantitative, real-time PCR”, Gene Therapy, 2004, pp. 1057-1067, vol. 11.
[cited by applicant]
Jones et al., “Who Should Receive Biologic Therapy for IBD? The Rationale for the Application of a Personalized Approach”, Gastroenterol Clin North Am, 2014, pp. 425-440, vol. 43.
[cited by applicant]
Kang et al., “Therapeutic uses of anti-interleukin-6 receptor antibody”, International Immunology, 2014, pp. 21-29, vol. 27:1.
[cited by applicant]
Keswani et al., “Pseudotyped Adeno-associated Viral Vector Tropism and Transduction Efficiencies in Murine Wound Healing”, Wound Repair Regen, 2012, pp. 592-600, vol. 20:4.
[cited by applicant]
Kim et al., “Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping”, Nat Biotechnol, 2004, pp. 93-97, vol. 22:1.
[cited by applicant]
Koller, “Targeted therapy in rheumatoid arthritis”, Wien Med Wochenschr, 2006, pp. 53-60, vol. 156:1-2.
[cited by applicant]
Korkmaz et al., “Therapeutic intradermal delivery of tumor necrosis factor-alpha antibodies using tip-loaded dissolvable microneedle arrays”, Acta Biomaterialia, 2015, pp. 96-105, vol. 24.
[cited by applicant]
Kupetsky et al., “Anti-cytokine therapy in the treatment of psoriasis”, Cytokine, 2013, pp. 704-712, vol. 61.
[cited by applicant]
Lallemand et al., “Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFa antagonists”, Journal of Immunological Methods, 2011, pp. 229-239, vol. 373.
[cited by applicant]
Lee et al., “Current concepts in the diagnosis and management of cytokine release syndrome”, Blood, 2014, pp. 188-195, vol. 124:2.
[cited by applicant]
Mandrup-Poulsenon, “Interleukin-1 antagonists for diabetes”, Expert Opinion on Investigational Drugs, 2013, pp. 965-979, vol. 22:8.
[cited by applicant]
Marshall et al., “Near-Infrared Fluorescence Imaging in Humans with Indocyanine Green: A Review and Update”, Open Surg Oncol J., 2012, pp. 12-25, vol. 2, No. 2.
[cited by applicant]
Mattocks et al., “A standardized framework for the validation and verification of clinical molecular genetics tests”, European Journal of Human Genetics, 2010, pp. 1276-1288, vol. 18.
[cited by applicant]
Maude et al., “Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies”, Cancer J, 2014, pp. 119-122, vol. 20:2.
[cited by applicant]
Meglinski et al., “Quantitative assessment of skin layers absorption and skin reflectance spectra simulation in the visible and near-infrared spectral regions”, Physiological Measurement, 2002, pp. 741-753, vol. 23:4.
[cited by applicant]
Merten et al., “Current issues in adeno-associated viral vector production”, Gene Therapy, 2005, pp. S51-S61, vol. 12.
[cited by applicant]
Milman et al., “Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis”, Clinical Biochemistry, 2010, pp. 1309-1314, vol. 43.
[cited by applicant]
Monaco et al., “Anti-TNF therapy: past, present and future”, International Immunology, 2014, pp. 55-62, vol. 27:1.
[cited by applicant]
Monteleone et al., “Targets for new immunomodulation strategies in inflammatory bowel disease”, Autoimmunity Reviews, 2014, pp. 11-14, vol. 13.
[cited by applicant]
Morozova et al., “Far-Red Fluorescent Protein Excitable with Red Lasers for Flow Cytometry and Superresolution STED Nanoscopy”, Biophysical Journal, 2010, pp. L13-L15, vol. 99.
[cited by applicant]
Muller-Ladner, et al., “Role of Nuclear Factor κB in Synovial Inflammation”, Current Rheumatology Reports, 2002, pp. 201-207, vol. 4.
[cited by applicant]
Nograles et al., “Anti-cytokine therapies for psoriasis”, Experimental Cell Research, 2011, pp. 1293-1300, vol. 317.
[cited by applicant]
Papoutsaki et al., “Treatment of Psoriasis and Psoriatic Arthritis”, Biodrugs, 2013, pp. 3-12, vol. 27:1.
[cited by applicant]
Perabo et al., “Heparan Sulfate Proteoglycan Binding Properties of Adeno-Associated Virus Retargeting Mutants and Consequences for Their In Vivo Tropism”, Journal of Virology, 2006, pp. 7265-7269, vol. 80:14.
[cited by applicant]
Piatkevich et al., “Guide to Red Fluorescent Proteins and Biosensors for Flow Cytometry”, Methods Cell Biol., 2011, pp. 431-461, vol. 102.
[cited by applicant]
Pras et al., “Intraocular Inflammation in Autoimmune Diseases”, Seminars in Arthritis and Rheumatism, 2004, pp. 602-609, vol. 34.
[cited by applicant]
Prausnitz et al., “Microneedle-based vaccines”, Curr Top Microbiol Immunol, 2009, pp. 369-393, vol. 333.
[cited by applicant]
Prelog, “Vaccination in Patients with Rheumatoid Arthritis Receiving Immunotherapies”, Clinical & Cellular Immunology, 2013, pp. 1-10, vol. S6.
[cited by applicant]
PscAAV-MCS Expression Vector, Product Data Sheet, Cell Biolabs, Inc., San Diego, California (2015).
[cited by applicant]
Pusztai et al., “Clinical trial design for microarray predictive marker discovery and assessment”, Annals of Oncology, 2004, pp. 1731-1737, vol. 15.
[cited by applicant]
Qin et al., “Systematic Comparison of Constitutive Promoters and the Doxycycline-Inducible Promoter”, PLoS One, 2010, pp. 1-4, vol. 5:5.
[cited by applicant]
Qiu et al., “The Interaction of Heparin Sulfate and Adeno-Associated Virus 2”, Virology, 2000, pp. 137-147, vol. 269.
[cited by applicant]
Quan et al., “Long-Term Protective Immunity from an Influenza Virus-Like Particle Vaccine Administered with a Microneedle Patch”, Clinical and Vaccine Immunology, 2013, pp. 1433-1439, vol. 20:9.
[cited by applicant]
Reynolds et al., “Emerging immunotherapies for rheumatoid arthritis”, Human Vaccines & Immunotherapeutics, 2014, pp. 822-837, vol. 10:4.
[cited by applicant]
Rosenbloom et al., “In vitro and in vivo protein sampling by combined microdialysis and ultrafiltration”, Journal of Immunological Methods, 2006, pp. 55-68, vol. 309.
[cited by applicant]
Rossi et al., “Interleukin-6 as a Therapeutic Target”, Clinical Cancer Research, 2015, pp. 1248-1257, vol. 21:6.
[cited by applicant]
Salgo et al., “Microdialysis documents changes in the micromilieu of psoriatic plaques under continuous systemic therapy”, Experimental Dermatology, 2011, pp. 130-133, vol. 20.
[cited by applicant]
Sallach et al., “Tropism-modified AAV Vectors Overcome Barriers to Successful Cutaneous Therapy”, Molecular Therapy, 2014, pp. 929-939, vol. 22:5.
[cited by applicant]
Samulski et al., “AAV-Mediated Gene Therapy for Research and Therapeutic Purposes”, Annual Review of Virology, 2014, pp. 427-451, vol. 1.
[cited by applicant]
Shcherbakova et al., “Near-infrared fluorescent proteins for multicolor in vivo imaging”, Nat Methods, 2013, pp. 751-754, vol. 10:8.
[cited by applicant]
Shu et al., “Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome”, Science, 2009, pp. 804-807, vol. 324:5928.
[cited by applicant]
Sikorski et al., “STAT1 as a central mediator of IFNy and TLR4 signal integration in vascular dysfunction”, JAK-STAT, 2012, pp. 241-249, vol. 1:4.
[cited by applicant]
Sjogren et al., “Are Cutaneous Microdialysis Cytokine Findings Supported by End Point Biopsy Immunohistochemistry Findings?”, AAPS Journal, 2010, pp. 741-749, vol. 12:4.
[cited by applicant]
Sjogren et al., “Cutaneous Microdialysis: Cytokine Evidence for Altered Innate Reactivity in the Skin of Psoriasis Patients?”, AAPS Journal, 2012, pp. 187-195, vol. 14:2.
[cited by applicant]
Srivastava et al., ““Smart tattoo” Glucose Biosensors and Effect of Coencapsulated Anti-Inflammatory Agents”, Journal of Diabetes Science and Technology, 2011, pp. 76-85, vol. 5:1.
[cited by applicant]
Steenholdt et al., “Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Tria…
[cited by applicant]
Steenholdt et al., “Cut-off levels and diagnostic accuracy of infliximab trough levels and antiinfliximab antibodies in Crohn's disease”, Scandinavian Journal of Gastroenterology, 2011, pp. 310-318, vol. 46:3.
[cited by applicant]
Steenholdt, “Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease”, Danish Medical Journal, 2013, pp. 1-24, vol. 6…
[cited by applicant]
Swindell et al., “Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites”, Clinical and translational medicine, 2015, pp. 1/21-3/21, vol. 4:13.
[cited by applicant]
Tanaka et al., “Image-Guided Oncologic Surgery Using Invisible Light: Completed Pre-Clinical Development for Sentinel Lymph Node Mapping”, Ann Surg Oncol., 2006, pp. 1671-1681, vol. 13:12.
[cited by applicant]